Skip to main content
. 2019 Jun;95(6):629–637. doi: 10.1124/mol.118.115386

Fig. 2.

Fig. 2.

Treatment of RASMCs with FoxO inhibitor drug AS1842856 shows concentration-dependent decrease in sGC mRNA and protein expression. AS1842856 FoxO inhibitor drug structure (A) and effect on sGC α mRNA expression (B) or sGC β mRNA expression (C) following 48-hour drug treatment. (D) Western blot and quantification of 48-hour treatment with FoxO inhibitor on sGC α protein expression (E) and sGC β protein expression (F). n = 3 for all samples. One-way ANOVA test was used for determination of significance. ***P < 0.001; ****P < 0.0001. Error bars represent S.D.